TY - JOUR
T1 - Auranofin is an effective agent against clinical isolates of Staphylococcus aureus
AU - Tharmalingam, Nagendran
AU - Ribeiro, Noelly Q.
AU - Da Silva, Danielle L.
AU - Naik, Mandar T.
AU - Cruz, Lana I.B.
AU - Kim, Wooseong
AU - Shen, Steven
AU - Dos Santos, Jéssica D.
AU - Ezikovich, Katarina
AU - D'Agata, Erika M.C.
AU - Mylonakis, Eleftherios
AU - Fuchs, Beth B.
N1 - Funding Information:
Funding was made available to EMCD through an award from the National Institute of Allergy and Infectious Diseases (K24 AI119158). The research was also funded through an National Institute of Health grant (P20GM121344). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Funding Information:
Made available to EMCD through an award from the National Institute of Allergy and Infectious Diseases (K24 AI119158). The research was also funded through an National Institute of Health grant (P20GM121344). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2019 Newlands Press.
PY - 2019
Y1 - 2019
N2 - Aim: The orphan drug auranofin was recently found to exhibit antimicrobial properties. Materials & methods: We explored the efficacy of auranofin by evaluating the minimal inhibitory concentration against a collection of over 500 clinical isolates derived from multiple institutions, inclusive of drug resistant strains. Our evaluation also included continuous exposure of bacteria to auranofin. Results & conclusion: We found that minimal inhibitory concentrations ranged between 0.125 and 1 mg/l, exerting robust antimicrobial activity against a sizeable clinical collection of the bacteria. Further, we evaluated the propensity of the methicillin-resistant Staphylococcus aureus strain MW2 to develop resistance through extended exposure to auranofin. After 25 days, the bacteria remained susceptible. Our data suggest that resistance mechanisms do not currently exist to block auranofin antimicrobial activity.
AB - Aim: The orphan drug auranofin was recently found to exhibit antimicrobial properties. Materials & methods: We explored the efficacy of auranofin by evaluating the minimal inhibitory concentration against a collection of over 500 clinical isolates derived from multiple institutions, inclusive of drug resistant strains. Our evaluation also included continuous exposure of bacteria to auranofin. Results & conclusion: We found that minimal inhibitory concentrations ranged between 0.125 and 1 mg/l, exerting robust antimicrobial activity against a sizeable clinical collection of the bacteria. Further, we evaluated the propensity of the methicillin-resistant Staphylococcus aureus strain MW2 to develop resistance through extended exposure to auranofin. After 25 days, the bacteria remained susceptible. Our data suggest that resistance mechanisms do not currently exist to block auranofin antimicrobial activity.
KW - MRSA
KW - Staphylococcus aureus
KW - VISA
KW - antimicrobial
KW - auranofin
KW - drug-resistant bacteria
KW - thioredoxin reductase
UR - http://www.scopus.com/inward/record.url?scp=85070402920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070402920&partnerID=8YFLogxK
U2 - 10.4155/fmc-2018-0544
DO - 10.4155/fmc-2018-0544
M3 - Article
C2 - 31298580
AN - SCOPUS:85070402920
VL - 11
SP - 1417
EP - 1425
JO - Future Medicinal Chemistry
JF - Future Medicinal Chemistry
SN - 1756-8919
IS - 12
ER -